{"id":51322,"date":"2022-11-29T01:03:05","date_gmt":"2022-11-29T00:03:05","guid":{"rendered":"https:\/\/pharma-trend.com\/en\/touchlight-receives-grant-to-advance-rapid-scalable-and-thermostable-doggybone-dna-vaccine-platform\/"},"modified":"2022-11-29T01:03:05","modified_gmt":"2022-11-29T00:03:05","slug":"touchlight-receives-grant-to-advance-rapid-scalable-and-thermostable-doggybone-dna-vaccine-platform","status":"publish","type":"post","link":"https:\/\/pharma-trend.com\/en\/touchlight-receives-grant-to-advance-rapid-scalable-and-thermostable-doggybone-dna-vaccine-platform\/","title":{"rendered":"Touchlight receives grant to advance rapid, scalable and thermostable doggybone DNA vaccine platform"},"content":{"rendered":"
\n

\nFunding from the Bill & Melinda Gates Foundation will build on preclinical data showing the potential of nanoparticle-formulated doggybone DNA to deliver strong antibody titres and strong T cell responses.<\/i>\n<\/p>\n

HAMPTON, England–(BUSINESS WIRE)–Touchlight, a biotechnology company pioneering enzymatic DNA production to enable the genetic medicine revolution, is furthering pre-clinical development of its proprietary doggybone DNA vaccine platform, financed by a new grant received from the Bill & Melinda Gates Foundation.\n<\/p>\n

<\/a><\/p>\n

\nThe program aims to build on evidence that Touchlight\u2019s rapid enzymatic doggybone DNA vaccines can produce strong neutralising antibodies and durable T cell responses following vaccine administration in nanoparticles. As part of the grant, Touchlight will also be investigating the performance of doggybone DNA for therapeutic monoclonal antibody production.\n<\/p>\n

\nSuccessful demonstration of the doggybone DNA platform\u2019s effectiveness in DNA vaccine and gene therapy applications has the potential to support the global availability of innovative medicines and to further the application of the doggybone platform in enabling rapid pandemic response.\n<\/p>\n

\nKaren Fallen, CEO of Touchlight, commented: <\/b>\u201cThis grant is further evidence of the potential of our doggybone DNA platform. We are excited to start the program, which could potentially demonstrate that the doggybone DNA platform can support a rapid, scalable, durable and thermostable vaccine solution for future pandemic response.\u201d<\/i>\n<\/p>\n

\nTouchlight\u2019s enzymatic approach enables the rapid and scalable DNA manufacture in a significantly smaller footprint than can be achieved with fermentation-based processes. In addition, it eliminates antibiotic-resistance genes that could be present in plasmid DNA, improving safety.\n<\/p>\n

\nTouchlight\u2019s core focus is to enable genetic medicine by providing Contract Development and Manufacturing (CDMO) services to genetic medicine manufacturers, and doggybone DNA is already widely utilised across the genetic medicine market, in areas such as critical starting material for viral vector and mRNA vaccine production, genome editing and DNA vaccine applications.\n<\/p>\n

\nAbout Touchlight<\/b>\n<\/p>\n

\nTouchlight is a privately-owned company based in London, U.K., focused on the provision of DNA services and manufacture of enzymatically produced novel DNA formats, such as doggybone DNA (dbDNA\u2122) to enable the development of genetic medicines.\n<\/p>\n

\nTouchlight DNA Services provide rapid, enzymatic DNA development and manufacturing for all advanced therapy production, including mRNA, viral and non-viral gene therapy and DNA API. dbDNA is a minimal, linear, covalently closed structure, which eliminates bacterial sequences.\n<\/p>\n

\nTouchlight\u2019s revolutionary enzymatic production platform enables unprecedented speed, scale, and the ability to target genes with a size and complexity that is impossible with current technologies. Clients can be supported from pre-clinical through development and supply, to licencing and tech transfer for use in-house.\n<\/p>\n

\nFind out more at www.touchlight.com<\/a>
Follow Touchlight on LinkedIn<\/a>
Follow @TouchlightDNA on Twitter<\/a>\n<\/p>\n

Contacts<\/b> <\/p>\n

\nFor more information please contact:<\/p>\n

Touchlight<\/b>
Robin Bodicoat, Head of Marketing
\n
E: info@touchlight.com<\/a>
T: +44 20 8481 9200\n<\/p>\n

\nInstinctif Partners<\/b>
Agnes Stephens \/ Jonjo Cordey
\n
E: touchlight@instinctif.com<\/a>
T: +44 20 7457 2020\n<\/p>\n<\/div>\n","protected":false},"excerpt":{"rendered":"

Funding from the Bill & Melinda Gates Foundation will build on preclinical data showing the potential of nanoparticle-formulated doggybone DNA to deliver strong antibody titres and strong T cell responses. HAMPTON, England–(BUSINESS WIRE)–Touchlight, a biotechnology company pioneering enzymatic DNA production to enable the genetic medicine revolution, is furthering pre-clinical development of its proprietary doggybone DNA … [Read more…]<\/a><\/span><\/p>\n","protected":false},"author":4,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[13],"tags":[],"class_list":{"0":"entry","1":"post","2":"publish","3":"author-business","4":"post-51322","6":"format-standard","7":"category-industry"},"yoast_head":"\nTouchlight receives grant to advance rapid, scalable and thermostable doggybone DNA vaccine platform - Pharma Trend<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/pharma-trend.com\/en\/touchlight-receives-grant-to-advance-rapid-scalable-and-thermostable-doggybone-dna-vaccine-platform\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Touchlight receives grant to advance rapid, scalable and thermostable doggybone DNA vaccine platform - Pharma Trend\" \/>\n<meta property=\"og:description\" content=\"Funding from the Bill & Melinda Gates Foundation will build on preclinical data showing the potential of nanoparticle-formulated doggybone DNA to deliver strong antibody titres and strong T cell responses. HAMPTON, England–(BUSINESS WIRE)–Touchlight, a biotechnology company pioneering enzymatic DNA production to enable the genetic medicine revolution, is furthering pre-clinical development of its proprietary doggybone DNA ... [Read more...]\" \/>\n<meta property=\"og:url\" content=\"https:\/\/pharma-trend.com\/en\/touchlight-receives-grant-to-advance-rapid-scalable-and-thermostable-doggybone-dna-vaccine-platform\/\" \/>\n<meta property=\"og:site_name\" content=\"Pharma Trend\" \/>\n<meta property=\"article:published_time\" content=\"2022-11-29T00:03:05+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/mms.businesswire.com\/media\/20221124005166\/en\/1646693\/21\/Touchlight_logo.jpg\" \/>\n<meta name=\"author\" content=\"Business Wire\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Business Wire\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/touchlight-receives-grant-to-advance-rapid-scalable-and-thermostable-doggybone-dna-vaccine-platform\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/touchlight-receives-grant-to-advance-rapid-scalable-and-thermostable-doggybone-dna-vaccine-platform\\\/\"},\"author\":{\"name\":\"Business Wire\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/person\\\/02d41342c7a74fa7f0032bb35ef0bb24\"},\"headline\":\"Touchlight receives grant to advance rapid, scalable and thermostable doggybone DNA vaccine platform\",\"datePublished\":\"2022-11-29T00:03:05+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/touchlight-receives-grant-to-advance-rapid-scalable-and-thermostable-doggybone-dna-vaccine-platform\\\/\"},\"wordCount\":480,\"publisher\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/touchlight-receives-grant-to-advance-rapid-scalable-and-thermostable-doggybone-dna-vaccine-platform\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20221124005166\\\/en\\\/1646693\\\/21\\\/Touchlight_logo.jpg\",\"articleSection\":[\"Industry\"],\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/touchlight-receives-grant-to-advance-rapid-scalable-and-thermostable-doggybone-dna-vaccine-platform\\\/\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/touchlight-receives-grant-to-advance-rapid-scalable-and-thermostable-doggybone-dna-vaccine-platform\\\/\",\"name\":\"Touchlight receives grant to advance rapid, scalable and thermostable doggybone DNA vaccine platform - Pharma Trend\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/touchlight-receives-grant-to-advance-rapid-scalable-and-thermostable-doggybone-dna-vaccine-platform\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/touchlight-receives-grant-to-advance-rapid-scalable-and-thermostable-doggybone-dna-vaccine-platform\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20221124005166\\\/en\\\/1646693\\\/21\\\/Touchlight_logo.jpg\",\"datePublished\":\"2022-11-29T00:03:05+00:00\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/touchlight-receives-grant-to-advance-rapid-scalable-and-thermostable-doggybone-dna-vaccine-platform\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/pharma-trend.com\\\/en\\\/touchlight-receives-grant-to-advance-rapid-scalable-and-thermostable-doggybone-dna-vaccine-platform\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/touchlight-receives-grant-to-advance-rapid-scalable-and-thermostable-doggybone-dna-vaccine-platform\\\/#primaryimage\",\"url\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20221124005166\\\/en\\\/1646693\\\/21\\\/Touchlight_logo.jpg\",\"contentUrl\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20221124005166\\\/en\\\/1646693\\\/21\\\/Touchlight_logo.jpg\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/touchlight-receives-grant-to-advance-rapid-scalable-and-thermostable-doggybone-dna-vaccine-platform\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Startseite\",\"item\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Touchlight receives grant to advance rapid, scalable and thermostable doggybone DNA vaccine platform\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#website\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\",\"name\":\"Pharma Trend\",\"description\":\"\",\"publisher\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\",\"name\":\"Pharma Trend\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"\",\"contentUrl\":\"\",\"caption\":\"Pharma Trend\"},\"image\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/logo\\\/image\\\/\"}},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/person\\\/02d41342c7a74fa7f0032bb35ef0bb24\",\"name\":\"Business Wire\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Touchlight receives grant to advance rapid, scalable and thermostable doggybone DNA vaccine platform - Pharma Trend","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/pharma-trend.com\/en\/touchlight-receives-grant-to-advance-rapid-scalable-and-thermostable-doggybone-dna-vaccine-platform\/","og_locale":"en_US","og_type":"article","og_title":"Touchlight receives grant to advance rapid, scalable and thermostable doggybone DNA vaccine platform - Pharma Trend","og_description":"Funding from the Bill & Melinda Gates Foundation will build on preclinical data showing the potential of nanoparticle-formulated doggybone DNA to deliver strong antibody titres and strong T cell responses. HAMPTON, England–(BUSINESS WIRE)–Touchlight, a biotechnology company pioneering enzymatic DNA production to enable the genetic medicine revolution, is furthering pre-clinical development of its proprietary doggybone DNA ... [Read more...]","og_url":"https:\/\/pharma-trend.com\/en\/touchlight-receives-grant-to-advance-rapid-scalable-and-thermostable-doggybone-dna-vaccine-platform\/","og_site_name":"Pharma Trend","article_published_time":"2022-11-29T00:03:05+00:00","og_image":[{"url":"https:\/\/mms.businesswire.com\/media\/20221124005166\/en\/1646693\/21\/Touchlight_logo.jpg","type":"","width":"","height":""}],"author":"Business Wire","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Business Wire","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/pharma-trend.com\/en\/touchlight-receives-grant-to-advance-rapid-scalable-and-thermostable-doggybone-dna-vaccine-platform\/#article","isPartOf":{"@id":"https:\/\/pharma-trend.com\/en\/touchlight-receives-grant-to-advance-rapid-scalable-and-thermostable-doggybone-dna-vaccine-platform\/"},"author":{"name":"Business Wire","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/person\/02d41342c7a74fa7f0032bb35ef0bb24"},"headline":"Touchlight receives grant to advance rapid, scalable and thermostable doggybone DNA vaccine platform","datePublished":"2022-11-29T00:03:05+00:00","mainEntityOfPage":{"@id":"https:\/\/pharma-trend.com\/en\/touchlight-receives-grant-to-advance-rapid-scalable-and-thermostable-doggybone-dna-vaccine-platform\/"},"wordCount":480,"publisher":{"@id":"https:\/\/pharma-trend.com\/en\/#organization"},"image":{"@id":"https:\/\/pharma-trend.com\/en\/touchlight-receives-grant-to-advance-rapid-scalable-and-thermostable-doggybone-dna-vaccine-platform\/#primaryimage"},"thumbnailUrl":"https:\/\/mms.businesswire.com\/media\/20221124005166\/en\/1646693\/21\/Touchlight_logo.jpg","articleSection":["Industry"],"inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/pharma-trend.com\/en\/touchlight-receives-grant-to-advance-rapid-scalable-and-thermostable-doggybone-dna-vaccine-platform\/","url":"https:\/\/pharma-trend.com\/en\/touchlight-receives-grant-to-advance-rapid-scalable-and-thermostable-doggybone-dna-vaccine-platform\/","name":"Touchlight receives grant to advance rapid, scalable and thermostable doggybone DNA vaccine platform - Pharma Trend","isPartOf":{"@id":"https:\/\/pharma-trend.com\/en\/#website"},"primaryImageOfPage":{"@id":"https:\/\/pharma-trend.com\/en\/touchlight-receives-grant-to-advance-rapid-scalable-and-thermostable-doggybone-dna-vaccine-platform\/#primaryimage"},"image":{"@id":"https:\/\/pharma-trend.com\/en\/touchlight-receives-grant-to-advance-rapid-scalable-and-thermostable-doggybone-dna-vaccine-platform\/#primaryimage"},"thumbnailUrl":"https:\/\/mms.businesswire.com\/media\/20221124005166\/en\/1646693\/21\/Touchlight_logo.jpg","datePublished":"2022-11-29T00:03:05+00:00","breadcrumb":{"@id":"https:\/\/pharma-trend.com\/en\/touchlight-receives-grant-to-advance-rapid-scalable-and-thermostable-doggybone-dna-vaccine-platform\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/pharma-trend.com\/en\/touchlight-receives-grant-to-advance-rapid-scalable-and-thermostable-doggybone-dna-vaccine-platform\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/pharma-trend.com\/en\/touchlight-receives-grant-to-advance-rapid-scalable-and-thermostable-doggybone-dna-vaccine-platform\/#primaryimage","url":"https:\/\/mms.businesswire.com\/media\/20221124005166\/en\/1646693\/21\/Touchlight_logo.jpg","contentUrl":"https:\/\/mms.businesswire.com\/media\/20221124005166\/en\/1646693\/21\/Touchlight_logo.jpg"},{"@type":"BreadcrumbList","@id":"https:\/\/pharma-trend.com\/en\/touchlight-receives-grant-to-advance-rapid-scalable-and-thermostable-doggybone-dna-vaccine-platform\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Startseite","item":"https:\/\/pharma-trend.com\/en\/"},{"@type":"ListItem","position":2,"name":"Touchlight receives grant to advance rapid, scalable and thermostable doggybone DNA vaccine platform"}]},{"@type":"WebSite","@id":"https:\/\/pharma-trend.com\/en\/#website","url":"https:\/\/pharma-trend.com\/en\/","name":"Pharma Trend","description":"","publisher":{"@id":"https:\/\/pharma-trend.com\/en\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/pharma-trend.com\/en\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/pharma-trend.com\/en\/#organization","name":"Pharma Trend","url":"https:\/\/pharma-trend.com\/en\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/logo\/image\/","url":"","contentUrl":"","caption":"Pharma Trend"},"image":{"@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/logo\/image\/"}},{"@type":"Person","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/person\/02d41342c7a74fa7f0032bb35ef0bb24","name":"Business Wire"}]}},"_links":{"self":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts\/51322","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/users\/4"}],"replies":[{"embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/comments?post=51322"}],"version-history":[{"count":0,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts\/51322\/revisions"}],"wp:attachment":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/media?parent=51322"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/categories?post=51322"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/tags?post=51322"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}